Molecular treatments in Duchenne muscular dystrophy

Michela Guglieri, Kate Bushby
Current Opinion in Pharmacology 2010, 10 (3): 331-7
Duchenne muscular dystrophy (DMD) is the most common childhood muscular dystrophy and results from mutations in the dystrophin gene. Currently no treatment is available for this devastating condition. Standards of care have been improving and are spreading world-wide, prolonging survival and increasing quality of life, however management of symptoms and complications remains the only interventions that can currently be offered to patients. New and promising experimental strategies to address DMD have been developed over the last few years and some of them are in or are approaching clinical trials. Different therapeutic options are being investigated, ranging from mutation-specific treatments, including nonsense codon suppressors and exon skipping, to gene therapy using viral and nonviral vectors and cell-based approaches. Here we review the current status of molecular investigational treatments in DMD, with a particular focus on those compounds and strategies that are currently in clinical trials or are likely to approach clinical application in the near future.

Full Text Links

Find Full Text Links for this Article


You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"